Lumos Pharma Company Overview
Lumos Pharma
About Lumos Pharma
Lumos Pharma (NASDAQ:LUMO) specializes in developing innovative therapies for rare diseases with a primary focus on growth disorders. Aiming to significantly improve patients' lives, their flagship project revolves around a novel treatment for Pediatric Growth Hormone Deficiency, showcasing their commitment to addressing unmet medical needs in the rare disease community. Lumos Pharma operates with the objective to leverage cutting-edge science for creating breakthrough treatments that can lead to better health outcomes for those affected by rare and neglected conditions.
What is Lumos Pharma known for?
Snapshot
1999
Year founded
33
Employees
Ames, United States
Head office
Loading Map...
Operations
All Locations
United States
Products and/or services of Lumos Pharma
- Development of LUM-201, oral therapy aimed at pediatric growth hormone deficiency.
- Researching treatments for rare diseases with a focus on endocrine disorders.
- Advancement of therapies targeting genetic disorders leading to growth deficiencies.
- Collaboration with academic and medical institutions for clinical trials on novel therapeutics.
- Provision of comprehensive support services for patients and healthcare professionals involved in their trials.
- Investment in cutting-edge biopharmaceutical research to explore innovative treatment options.
Lumos Pharma executive team
- Mr. Richard J. HawkinsFounder, CEO & Chairman
- Dr. John C. McKew Ph.D.Chief Scientific Officer & President
- Ms. Lori D. Lawley CPACFO & Principal Accounting Officer
- Ms. Lisa Wells MillerSenior Director of Investor Relations
- Mr. Bradley J. Powers J.D.Chief Compliance Officer & General Counsel
- Mr. Aaron Schuchart B.B.A., CPA, M.B.A.Chief Business Officer
- Dr. Pisit Pitukcheewanont FAAP, M.D.Chief Medical Officer
- Ms. Alpa ParikhSenior Vice President of CMC & Supply Management
- Mr. Eddie L. Varnado M.B.A.Corporate Controller